| Ayoxxa–Prosnav Capital: investment, 202203– financing round providing runway for 3-5 years incl new + lead investor Prosnav Capital NOT REALISED |
2022-03-14 |
| Ayoxxa–ROI Verwaltungsgesellschaft: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Oetker Family Office |
2022-03-14 |
| Ayoxxa–SEVERAL: investment, 202203– financing round providing runway for 3-5 years led by new investor Prosnav Capital NOT REALISED |
2022-03-14 |
| Ayoxxa–Wellington Partners: investment, 202203 financing round providing runway for 3-5 years incl existing + co-investor Wellington Partners |
2022-03-14 |
| FGen–Ginkgo Bioworks: investment, 202203– acquisition of FGen AG by Ginkgo Bioworks for upfront payment + milestones ANNOUNCED |
2022-03-14 |
| Ginkgo Bioworks–FGen: screening technology, 202203 collab existent for several years |
2022-03-14 |
| Opto Biolabs–PERSON: investment, 202203 existent business angel investor Matthias Bissinger |
2022-03-10 |
| Opto Biolabs–PERSON: investment, 202203 existent business angel investor Philipp Baaske |
2022-03-10 |
| Roche–Scenic Biotech: drugs targeting genetic modifiers, 202203 collab multi-year multi-target existent with Genentech |
2022-03-10 |
| Scenic Biotech–BioMedPartners: investment, 202203 financing round Series A totalling €28m incl new + co-lead investor BioMedPartners |
2022-03-10 |
| Scenic Biotech–SEVERAL: investment, 202203 financing round Series A €28m co-led by Eir Ventures + BioMedPartners + Vesalius Biocapital |
2022-03-10 |
| Merck (DE)–Celeris Therapeutics: AI-based drug discovery, 202202– collab research small molecule binders + bifunctional degraders |
2022-03-09 |
| NEC–Vaximm: cancer vaccines, 202203 acquisition of all neoantigen cancer vaccines assets by NEC OncoImmunity |
2022-03-08 |
| Eurazeo–SEVERAL: investment, 202203 first closing €160m of Kurma Partners Growth Opportunities Fund targeting €250m |
2022-03-07 |
| Proteona–Singleron: investment, 202203 acquisition of Proteona Pte Ltd by Singleron Biotechnologies |
2022-03-07 |
| ArrePath–Boehringer: investment, 202203 seed financing round totalling $20m incl co-lead investor BIVF |
2022-03-03 |
| ArrePath–SEVERAL: investment, 202203 seed financing round $20m co-led by BIVF + Insight Partners + Innospark Ventures |
2022-03-03 |
| Epsilogen–Novartis: investment, 202203 financing round Series B totalling £30.75m incl new + lead investor Novartis Venture Fund |
2022-03-02 |
| Epsilogen–SEVERAL: investment, 202203 financing round Series B £30.75m led by new investor Novartis Venture Fund |
2022-03-02 |
| BioEcho–Ampersand: investment, 202203 minority growth equity investment €na from Ampersand Capital Partners |
2022-03-01 |
| In Ovo–ABN AMRO: investment, 202203 financing round totalling €34m incl new investor ABN AMRO |
2022-03-01 |
| In Ovo–ECBF: investment, 202203 financing round totalling €34m incl new investor ECBF |
2022-03-01 |
| In Ovo–Evonik: investment, 202203 financing round totalling €34m incl existing investor Evonik |
2022-03-01 |
| In Ovo–SEVERAL: investment, 202203 financing round €34m with ECBF + ABN AMRO et al |
2022-03-01 |
| Heidelberg Pharma–SEVERAL: investment, 202202–202208 capital increase €79.91m with €76.24m thereof from Huadong Medicine reaching 25% shareholding |
2022-02-27 |
| Aphea.Bio–ECBF: investment, 202202 existent investment of ECBF |
2022-02-23 |
| Complement Therapeutics–BioGeneration Ventures: investment, 202202 seed financing round totalling €5m incl BGV |
2022-02-23 |
| Complement Therapeutics–Forbion: investment, 202202 seed financing round totalling €5m incl Forbion |
2022-02-23 |
| Kumovis–3D Systems: investment, 202202– acquisition of Kumovis by 3D Systems |
2022-02-23 |
| Ampersand–Recipharm: investment, 202202–202204 acquisition of Arranta Bio by Recipharm AB |
2022-02-18 |
| Ampersand–Recipharm: investment, 202202–202204 acquisition of Vibalogics by Recipharm AB |
2022-02-18 |
| Centauri Therapeutics–SEVERAL: investment, 202202 financing round Series A £24m with BIVF + Evotec + Novo REPAIR Impact Fund et al |
2022-02-16 |
| Climedo Health–SEVERAL: investment, 202202 seed financing round €5m led by Nauta Capital |
2022-02-16 |
| ITM–Grand Pharma: investment, 202202 equity investment €25m from strategic partner Grand Pharmaceutical Group Ltd |
2022-02-16 |
| Memo Therapeutics–SEVERAL: investment, 202202 financing round Series B 2nd closing CHF23m bringing total round to CHF37m |
2022-02-16 |
| SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital |
2022-02-16 |
| XO Life–SEVERAL: investment, 202202 financing round more than €2m from SeedLink + MediVentures + Aescuvest et al |
2022-02-16 |
| c-LEcta–Kerry Group: investment, 202202 acquisition 92% for €137m with management to retain balance of shares |
2022-02-15 |
| c-LEcta–SHS Capital: investment, 202202 DIVESTMENT EXIT by SHS with sale of c-Lecta to Kerry Group |
2022-02-15 |
| IMIDomics–Evotec: investment, 202202 strategic equity investment €na by Evotec |
2022-02-15 |
| NMD Pharma–Roche: investment, 202202 financing round totalling €35m incl existing + co-investor Roche Venture Fund |
2022-02-15 |
| NMD Pharma–SEVERAL: investment, 202202 financing round €35m led by new investor Jeito Capital + incl existing investors |
2022-02-15 |
| Sequana Medical –Newton Biocapital: investment, before 202202 former pre-IPO early-exit investment of NBC I fund |
2022-02-15 |
| Green Elephant Biotech–Hessen (govt): investment, 202201 pre-seed financing round totalling mid-6-digit € incl lead investor BMH |
2022-02-11 |
| Green Elephant Biotech–OTHER: investment, 202201 pre-seed financing round totalling mid-6-digit € incl business angels as co-investors |
2022-02-11 |
| Green Elephant Biotech–SEVERAL: investment, 202201 pre-seed financing round mid-6-digit € led by BMH with business angels |
2022-02-11 |
| Celeris Therapeutics–Apex Ventures: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Apex Ventures |
2022-02-10 |
| Celeris Therapeutics–i&i Biotech Fund: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor i&i Biotech Fund |
2022-02-10 |
| Celeris Therapeutics–Longevitytech.fund: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor Longevitytech.fund |
2022-02-10 |
| Celeris Therapeutics–Pace Ventures Enigma: investment, 202202 seed financing round totalling $4.4m incl new + co-lead investor Pace Ventures Enigma |
2022-02-10 |
| Celeris Therapeutics–R42 Group: investment, 202202 seed financing round totalling $4.4m incl existing + co-investor R42 Group |
2022-02-10 |
| Celeris Therapeutics–SEVERAL: investment, 202202 seed financing round $4.4m led by Pace Ventures Enigma + i&i Biotech Fund + Apex Ventures |
2022-02-10 |
| Haya Therapeutics–4See Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor 4See Ventures |
2022-02-09 |
| Haya Therapeutics–Apollo Health Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Apollo HV |
2022-02-09 |
| Haya Therapeutics–Bernina BioInvest: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Bernina BioInvest |
2022-02-09 |
| Haya Therapeutics–Broadview Ventures: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Broadview Ventures |
2022-02-09 |
| Haya Therapeutics–Humboldt Fund: investment, 202202 seed financing round extension totalling $5m incl new + lead investor Humboldt Fund |
2022-02-09 |
| Haya Therapeutics–Schroders: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Schroder Adveq |
2022-02-09 |
| Haya Therapeutics–SEVERAL: investment, 202202 seed financing round extension $5m led by new investor Humboldt Fund |
2022-02-09 |
| Haya Therapeutics–Viva Biotech: investment, 202202 seed financing round extension totalling $5m incl existing + co-investor Viva BioInnovator |
2022-02-09 |
| Lindis Blood Care–Brandenburg (govt): investment, 202202 follow-on financing round incl existing + co-lead investor Brandenburg Kapital |
2022-02-09 |
| Lindis Blood Care–High-Tech Gründerfonds: investment, 202202 follow-on financing round incl existing + co-lead investor HTGF |
2022-02-09 |
| Lindis Blood Care–MC Services: public relations, 202202 service existent by MC Services |
2022-02-09 |
| Lindis Blood Care–OTHER: investment, 202202 follow-on financing round incl several private investors |
2022-02-09 |
| Lindis Blood Care–SEVERAL: investment, 202202 follow-on financing round led by HTGF + Brandenburg Kapital + several private investors |
2022-02-09 |
| Protix–ECBF: investment, 202202 financing round totalling €50m incl investor ECBF |
2022-02-09 |
| Protix–SEVERAL: investment, 202202 financing round €50m from ECBF + BNP Paribas et al |
2022-02-09 |
| Formo–BRAIN Biotech: genome editing technology, 202202– collab using CRISPR BEC platform to scale production of bioidentical milk protein |
2022-02-08 |
| In-Part–Inova Software: investment, 202202 acquisition of In-Part by Inova |
2022-02-08 |
| Elicit Plant–ECBF: investment, 202202 equity component €na of €16m funding round incl co-investor ECBF |
2022-02-07 |
| Elicit Plant–SEVERAL: investment, 202202 equity component €na led by Sofinnova Partners as part of funding round totalling €16m |
2022-02-07 |
| iOmx Therapeutics–MC Services: public relations, 202202 service existent by MC Services |
2022-02-03 |
| Merck (DE)–eTheRNA: mRNA technology, 202202– collab research using eTheRNA’s mRNA + LNP technologies to evaluate therapeutic feasibility |
2022-02-03 |
| Nemis Technologies–SEVERAL: investment, 202202 financing round Series A CHF7.75m from institutional + private investors |
2022-02-03 |
| Weriol Group–BRAIN Biotech: investment, 202202 acquisition of 62% of Breatec/Comix for €3.7m upfront + option to acquire remaining shares until 2027Q1 |
2022-02-03 |
| Ethris–Laureus Capital: investment, 202201 financing round Series B totalling €23.3m inc lead investor Laureus Capital |
2022-02-01 |
| Ethris–SEVERAL: investment, 202201 financing round Series B €23.3m led by Laureus Capital |
2022-02-01 |
| Ethris–Trophic Communications: public relations, 202201 service existent by Trophic |
2022-02-01 |
| Glycotope–Canton Biologics: investment, 202201 acquisition of newly formed FyoniBio GmbH from Glycotope by CantonBio Deutschland GmbH |
2022-02-01 |
| myPOLS Biotec–Medix Biochemica: investment, 202202 acquisition 100% of myPOLS Biotec GmbH by Medix Biochemica |
2022-02-01 |
| Noventi–Temedica: healthcare data analytics, 202202– collab using Permea system to advance healthcare research with real-world data |
2022-02-01 |
| Pharvaris–BRAIN Biotech: drug discovery services, 202202–202307 collab extension 9 months RnD bradykinin-B2-receptor antagonists Analyticon Discovery |
2022-02-01 |
| Zetta Genomics–SEVERAL: investment, 202202 seed financing round £2.5m with Cambridge Enterprise + Apex Ventures + Nina Capital |
2022-02-01 |
| Gandeeva Therapeutics–Bayer: investment, 202201 financing round Series A totalling $40m incl co-lead investor Leaps by Bayer |
2022-01-31 |
| Gandeeva Therapeutics–SEVERAL: investment, 202201 financing round Series A $40m led by Lux Capital + Leaps by Bayer |
2022-01-31 |
| Ribbon Biolabs–SEVERAL: investment, 202201 financing round Series A €18m led by Hadean Ventures |
2022-01-31 |
| Ribbon Biolabs–Trophic Communications: public relations, 202201 service existent by Trophic |
2022-01-31 |
| xbird–Glooko: investment, 202201 acquisition of xbird GmbH by Glooko Inc |
2022-01-31 |
| Mainz Biomed–SEVERAL: investment, 202201 public follow-on offering $22.5m+$3.375m with 1.725m+225k common shares at $15/share |
2022-01-28 |
| Cellino–Bayer: investment, 202201 financing round Series A totalling $80m incl new + lead investor Leaps by Bayer |
2022-01-25 |
| Cellino–SEVERAL: investment, 202201 financing round Series A $80m led by Leaps by Bayer + 8VC + Humboldt Fund |
2022-01-25 |
| Cytovation–SEVERAL: investment, 202201 financing round Series A NOK180m (€20m) led by Sandwater + Canica |
2022-01-25 |
| InstaDeep–BioNTech: investment, 202201 financing round Series B totalling $100m incl co-investor BioNTech |
2022-01-25 |
| InstaDeep–BioNTech: investment, 202301– acquisition of all remaining InstaDeep shares for £362m upfront in cash + shares plus £200m milestones |
2022-01-25 |
| InstaDeep–SEVERAL: investment, 202201 financing round Series B $100m led by Alpha Intelligence Capital with CDIB |
2022-01-25 |
| Metagenomi–Bayer: investment, 202201 financing round Series B totalling $175m incl existing + co-investor Leaps by Bayer |
2022-01-25 |
| Metagenomi–SEVERAL: investment, 202201 financing round Series B $175m co-led by PFM Health Sciences + Farallon Capital Mgt + NN |
2022-01-25 |
| Ferring–Cyprumed: drug delivery technology, 202201– collab expansion RnD for oral drug delivery of peptide therapeutics |
2022-01-24 |
| Elastrin Therapeutics–Forever Healthy: investment, 202201 existent investment of Kizoo |
2022-01-21 |
| Lift BioSciences–Forever Healthy: investment, 202201 financing round totalling £5m incl existing + co-investor Kizoo Technology Ventures |
2022-01-21 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 8 9 10 ... 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
